ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,030.12
      -0.82%
      US Tech 100
      16,873.40
      -1.10%
      Dow Jones
      37,983.96
      -1.24%
      Brent Oil
      86.92
      -0.34%
      Bitcoin
      64,430.45
      0.23%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Alterity Therapeutics Limited (ATHE)

      7. Alterity Therapeutics Limited (ATHE) News

      ATHE Alterity Therapeutics Limited

      2.3087
      -0.0213 (-0.91%)
      Last Updated: 12:23:46
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      Alterity Therapeutics Limited ATHE NASDAQ Depository Receipt
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      -0.0213 -0.91% 2.3087 12:23:46
      Open Price Low Price High Price Close Price Prev Close
      2.30 2.2927 2.4689 2.33
      more quote information »

      Recent News

      Date Time Source Heading
      4/25/20248:52IHNWFeaturedCannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA
      4/17/202407:25GLOBEAlterity Therapeutics Parkinson’s Disease and Multiple..
      4/10/202407:25GLOBEAlterity Therapeutics to Present New Data on ATH434 at the..
      3/26/202410:25GLOBEAlterity Therapeutics Receives a A$3.9 Million Research &..
      2/20/202410:25GLOBEAlterity Therapeutics to Present New Data at the Upcoming..
      2/15/202417:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/15/202417:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
      2/06/202407:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
      1/31/202408:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/29/202407:24GLOBEAlterity Therapeutics to Participate in the ShareCafe Hidden..
      1/22/202407:25GLOBEAlterity Therapeutics Issues Shareholder Letter Highlighting..
      1/22/202406:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/18/202408:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/11/202417:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/11/202417:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/10/202406:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/08/202408:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/08/202408:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/08/202408:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/08/202408:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/05/202406:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/05/202406:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/02/202408:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/02/202408:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/02/202408:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/29/202308:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/29/202308:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/21/202308:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/21/202308:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/21/202300:30GLOBEAlterity Therapeutics Appoints Phillip Hains as Chief..
      12/04/202316:35GLOBEAlterity Therapeutics to Host Webcast to Discuss ATH434..
      12/04/202307:25GLOBEAlterity Therapeutics Reports Positive Efficacy Data for..
      11/27/202307:25GLOBEAlterity Therapeutics Announces Presentation of Novel..
      11/16/202307:25GLOBEAlterity Therapeutics Announces Presentation of New Data..
      11/08/202307:25GLOBEAlterity Therapeutics Completes Enrolment in ATH434-201..
      10/30/202307:25GLOBEAppendix 4C – Q1 FY24 Quarterly Cash Flow Report
      10/26/202300:15EDGAR2Form EFFECT - Notice of Effectiveness
      9/13/202306:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      8/31/202307:25GLOBEAlterity Therapeutics Presents New Data on Multiple System..
      8/23/202307:25GLOBEAlterity Therapeutics Granted New Composition of Matter..
      8/22/202307:25GLOBEAlterity Therapeutics Rare Disease Natural History Study to..
      8/15/202307:25GLOBEAlterity Therapeutics Receives a $4.74 million Research &..
      7/31/202307:52GLOBEAppendix 4C – Q4 FY23 Quarterly Cash Flow Report
      7/26/202307:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
      6/21/202307:25GLOBEAlterity Therapeutics to Present in MST Access Rare..
      5/30/202307:25GLOBEAlterity Therapeutics Initiates Second Phase 2 Study in Rare..
      5/19/202307:25GLOBEAlterity Therapeutics CEO David Stamler to Present at the..
      5/10/202307:25GLOBEAlterity Therapeutics Enrolls First Patient in Australia in..
      4/26/202307:25GLOBEAlterity Therapeutics Presents Promising Wearable Sensor..

      Your Recent History

      NASDAQ
      ATHE
      Alterity Therapeutics
      Delayed Upgrade Clock